Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Devimistat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat)
    Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat)

    28 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/28/2524126/28235/en/Cornerstone-Pharmaceuticals-Initiates-Phase-1-Trial-of-CPI-613-devimistat-in-Combination-with-Chemoradiation-for-the-Treatment-of-Advanced-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    28 Sep 2022
    Share Share
    Cornerstone Pharma to Present Data on CPI-613 From Open-Label PI Study at ESMO
    Cornerstone Pharma to Present Data on CPI-613 From Open-Label PI Study at ESMO

    27 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/27/2469477/28235/en/Cornerstone-Pharmaceuticals-to-Present-Pancreatic-Cancer-Data-on-CPI-613-Devimistat-From-Its-Open-Label-Phase-1-Study-at-the-European-Society-of-Medical-Oncology-ESMO-World-Congres.html

    GLOBENEWSWIRE
    27 Jun 2022
    Share Share
    Cornerstone Pharma Announces Published Data on CPI-613 as an Effective Approach
    Cornerstone Pharma Announces Published Data on CPI-613 as an Effective Approach

    16 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/16/2464300/28235/en/Cornerstone-Pharmaceuticals-Announces-Published-Data-on-CPI-613-Devimistat-as-an-Effective-Approach-to-Targeting-Carcinoma-Catabolism-UPDATE.html

    GLOBENEWSWIRE
    16 Jun 2022
    Share Share
    EMA Grants ODD to Cornerstone's CPI-613 (Devimistat) for Biliary Tract Cancer
    EMA Grants ODD to Cornerstone's CPI-613 (Devimistat) for Biliary Tract Cancer

    24 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/24/2449592/28235/en/European-Medicines-Agency-Grants-Orphan-Drug-Designation-to-Cornerstone-Pharmaceuticals-CPI-613-Devimistat-for-Treatment-of-Patients-with-Advanced-Unresectable-Biliary-Tract-Cancer.html

    GLOBENEWSWIRE
    24 May 2022
    Share Share
    Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer
    Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer

    18 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/18/2368484/28235/en/Rafael-Pharmaceuticals-Announces-Ongoing-Successful-Enrollment-and-Opening-of-Additional-Sites-for-Phase-2-Clinical-Trial-of-CPI-613-Devimistat-in-Combination-with-Gemcitabine-and-.html

    GLOBENEWSWIRE
    18 Jan 2022
    Share Share
    Rafael Pharma Completes Dose Escalation in APOLLO 613 Phase 1/2 Trial of CPI-613
    Rafael Pharma Completes Dose Escalation in APOLLO 613 Phase 1/2 Trial of CPI-613

    06 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/06/2362450/28235/en/Rafael-Pharmaceuticals-Announces-Successful-Completion-of-Dose-Escalation-with-No-Dose-Limiting-Toxicity-DLT-in-First-Cohort-of-APOLLO-613-Phase-1-2-Clinical-Trial-of-CPI-613-Devim.html

    GLOBENEWSWIRE
    06 Jan 2022
    Share Share